PRESENTLY, OVER 40 PLAYERS, BASED IN DIFFERENT REGIONS OF THE WORLD CLAIM TO OFFER BIOASSAY SERVICES FOR CELL

During our research, we were able to capture more than 40 players, which claims to offer bioassay services related for cell and gene therapies.
Report Link -https://www.rootsanalysis....

Amongst the total players offering bioassay services for cell and gene therapies, most of the players engaged in this domain were established before 1995. Of these, nine are headquartered in North America, while eight are based in Europe. Further, the industry witnessed the establishment of nine players, post 2010. Of these, five are based in North America, three in Europe and one in the Asia-Pacific region. In addition to this, all of the bioassay service providers (100%) are offering pre-developed assay. This is followed by 89% players that offer customized assays for cell and gene therapies.

For Customize report -https://www.rootsanalysis....

Further, as can be observed from the figure, 75% service providers claim to have the required capabilities to offer services related to immunoassay. Besides this, we came across two companies which offer all the aforementioned bioanalytical services. Examples of such players include (in alphabetical order), BioAgilytix and PPD Laboratories. It is worth highlighting that, of the total companies offering bioassay services, close to 60% offer services both in vitro as well as in vivo type of bioassay for cell and gene therapies.

As the figure represents, majority are mid-sized players (48%). Of these, most (25%) of companies have been established between 2000 to 2010. This is followed by the large firms (36%), of which companies established before 1945 are (in reverse chronological order of year of establishment) BD Biosciences (1897), Lonza (1897), SGS (1878), Siemens Healthineers (1847) and Merck KGaA (1668).

For free Insights - https://www.rootsanalysis....

Majority of the companies (89%) offer bioassay services for cell therapies, followed by 86% companies offering bioassay services for gene therapies. Further, immunoassay was found to be the most common bioanalytical service, provided by 75% companies. This is followed by potency assay and ELISA offered by 66% bioassay service providers.

For additional details, please visit – https://www.rootsanalysis....

You may also be interested in the following titles:
1. Global T-Cell Therapies Market (5th Edition): Industry Trends and Global Forecasts, 2021-2030
2. CAR-T Cell Therapies Market (3rd Edition): Industry Trends and Global Forecasts, 2021-2030
3. TCR-based Therapies Market: Industry Trends and Global Forecasts, 2021-2030
4. Cell and Gene Therapy CROs Market: Industry Trends and Global Forecasts (2nd Edition), 2021-2030
5. Gene Therapy Market (4th Edition): Industry Trends and Global Forecasts, 2020-2030

About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at inforootsanalysis.com

Contact Details
Ben Johnson
+1 (415) 800 3415
ben.johnsonrootsanalysis.com

Roots Analysis
Web: https://www.rootsanalysis....
LinkedIn: https://in.linkedin.com/co...
Twitter: https://twitter.com/RootsA...
Medium: https://medium.com/RootsA...
Pinterest: https://in.pinterest.com/R...
Quora: https://rootsanalysisinsig...

Antibody Contract Manufacturing Market, 2020-2030 by Roots Analysis

With over 100 therapeutic monoclonal antibodies and antibody-based products in the market, the demand for developing and manufacturing of such products is anticipated to increase beyond the capabilities of innovator companies alone

Roots Analysis has announced the addition of the “Antibody Contract Manufacturing Market, 2020-2030” report to its list of offerings.

Although biopharmaceuticals offer significant profit margins and have been proven to be effective in treating a myriad of diseases, they are generally associated with high costs of development and complex manufacturing protocols; this is true for antibody-based products as well. Presently, there are a number of companies that claim to offer end-to-end solutions, ranging from antibody development to commercial production. Further, prevalent trends suggest that sponsor companies are likely to continue relying on contract service providers for various aspects of antibody-based product development and manufacturing.

To order this 285+ page report, which features 100+ figures and 110+ tables, please visit this - https://www.rootsanalysis....

Key Market Insights

Over 100 CMOs presently claim to offer manufacturing services for antibodies
The Antibody Contract manufacturing market is currently dominated by the presence of small and mid-sized companies, which represent 70% of the industry stakeholders. It is also worth highlighting that more than 55% of CMOs claim to have the capabilities to manufacture antibodies across all scales of operation (preclinical, clinical and commercial).

More than 90% service providers are focused on the production of monoclonal antibodies
However, players based in Asia are now increasingly focusing on the development of bispecific antibodies for therapeutic use. It worth highlighting that close to 20% of the CMOs engaged in this domain claim to offer manufacturing services for both bispecific antibodies and antibody fragments.

Europe has emerged as a key manufacturing hub for antibody-based products
More than 120 manufacturing facilities have been established by various players, worldwide; of these, 40% are in Europe. Additionally, 40% of the total installed capacity is in Europe, followed by Asia. Some of the prominent regions in Asia include (in decreasing order of number of manufacturing facilities) China, South Korea, India, Japan and Taiwan.

More than 90 partnership agreements have been inked between 2013 and 2019
Majority of these agreements were focused on manufacturing of various types of antibodies. Other popular types of collaboration models include process development and manufacturing agreements (22%), product development and manufacturing agreements (10%) and licensing agreements (7%).

Multiple expansion initiatives were undertaken by CMOs between 2017 and 2019
More than 50% of such initiatives were reported to be focused on the expansion of manufacturing facilities, followed by building new facilities (38%). It is worth noting that close to 50% of the total number of expansion initiatives were undertaken in Europe, of which, 25% were in the UK.

Demand for therapeutic antibodies is anticipated to grow at a CAGR of 10%, during 2020-2025
Given the fact that there are a number of antibody-based products in the market, the commercial demand for antibodies is significantly higher than the clinical demand. Across the three major global regions, North America represent over half of the overall global manufacturing demand for antibodies.

North America and Europe are anticipated to capture over 70% of the market share by 2030
However, the market in the Asia is anticipated to grow at a relatively faster rate. Further, presently, more than 90% of the antibodies are being developed using mammalian expression systems, and this trend is unlikely to change significantly in short to mid-term.

To request a sample copy / brochure of this report, please visit this- https://www.rootsanalysis....

Key Questions Answered
 Who are the leading CMOs engaged in the production of antibody-based therapeutics?
 What kind of partnership models are commonly adopted by stakeholders in this industry?
 What is the annual clinical and commercial demand for antibody-based products?
 What is the current installed capacity for manufacturing of antibodies?
 What are the various expansion initiatives undertaken by antibody CMOs?
 How is the current and future market opportunity likely to be distributed across key market segments?

The USD 17 billion (by 2030) financial opportunity within the antibody contract manufacturing market has been analyzed across the following segments:
 Type of Antibodies
 Monoclonal Antibodies
 Bispecific Antibodies
 ADCs
 Others

 Company Size
 Small
 Mid-sized
 Large / Very Large

 Scale of Operation
 Preclinical / Clinical
 Commercial

 Type of expression system used
 Mammalian
 Microbial

 Key geographical regions
 North America
 Europe
 Asia and RoW

The report features inputs from eminent industry stakeholders, according to whom antibody therapeutics developers are increasingly outsourcing their manufacturing operations owing to complex nature of the overall process, as well as the high investments associated with setting-up in-house expertise. The report includes detailed transcripts of discussions held with the following experts:
 Dietmar Katinger (Chief Executive Officer, Polymun Scientific)
 David C Cunningham (Director, Corporate Development, Goodwin Biotechnology)
 Claire Otjes (Marketing Manager, Batavia Biosciences)

The research covers profiles of key players that offer manufacturing services for antibodies, featuring a company overview, information on their respective service portfolios, manufacturing facilities and ca

Novel Ocular Drug Delivery Devices Market: Focus on Implants, Inserts and Punctal Plugs, 2021-2030

There is an evident rise in the demand for effective, non-invasive drug delivery systems that are capable of overcoming bioavailability hurdles and enable delivery of the drug at the target cells, at effective concentrations, for a suitable period of time. In our research, 50 drug delivery devices that have been / are being developed by various industry players across the world.
To order this detailed 180+ page report, please visit this - https://www.rootsanalysis....

The novel ocular drug delivery market is highly fragmented, featuring the presence of established, as well as emerging players. Further, majority (75%) of the developers engaged in this domain are based in North America; examples, include (in alphabetical order) Aerie Pharmaceuticals, Alimera Sciences, Amorphex Therapeutics, Bausch and Lomb, EyePoint Pharmaceuticals and Genentech. This is followed by players headquartered in RoW (13%), Asia Pacific (6%) and Europe (6%).
To Request for sample - https://www.rootsanalysis....

Implants (80%) emerged as the most common type of combination device being developed by stakeholders engaged in this domain. As is evident from the figure, 43% candidates are being evaluated across different clinical phases, of which, 23% are in phase II trials and 15% are in phase I studies. topical emerged as the most popular (40%) route of administration, followed by intravitreal route (35%), adopted by novel ocular drug delivery devices. It is worth mentioning that topical route primarily targets the anterior eye diseases, while the intravitreal route is widely used for the treatment of posterior eye diseases.

Majority (88 %) of the combinational devices are being developed for delivery of small molecules, followed by biologic (12%). It is worth mentioning that, of these, 60% are biodegradable, followed by 40% of non-biodegradable devices. It is worth mentioning that biodegradable implants contain natural and synthetic polymers which can help in achieving controlled release of formulation for longer duration. Further, maximum number of combinational devices products are being developed for treatment of glaucoma (17); Examples include (in alphabetical order) Latanoprost (Mati Therapeutics), Durysta (Allergan), ENV515 (Aerie Pharmaceuticals), EXP-LP (Eximore), Glaucoma Implant (Polyactiva) and Glaucoma Implant (Polyactiva) Latanoprost (Mati Therapeutics). route primarily targets the anterior eye diseases, while the intravitreal route is widely used for the treatment of posterior eye diseases.

You may also be interested in the following titles:
1. Peptides and Macrocycle Drug Discovery: Services and Platforms Market, 2020 - 2030
2. China Biopharmaceutical Contract Manufacturing Market, 2020-2030
3. Antibody Contract Manufacturing Market, 2020 - 2030

About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at inforootsanalysis.com
Contact Details
Ben Johnson
+1 (415) 800 3415
ben.johnsonrootsanalysis.com

Roots Analysis
Web: https://www.rootsanalysis....
LinkedIn: https://in.linkedin.com/co...
Twitter: https://twitter.com/RootsA...
Medium: https://medium.com/RootsA...
Pinterest: https://in.pinterest.com/R...
Quora: https://rootsanalysisinsig...

Antibody Contract Manufacturing Market, 2020-2030 by Roots Analysis
With over 100 therapeutic monoclonal antibodies and antibody-based products in the market, the demand for developing and manufacturing of such products is anticipated to increase beyond the capabilities of innovator companies alone

Roots Analysis has announced the addition of the “Antibody Contract Manufacturing Market, 2020-2030” report to its list of offerings.

Although biopharmaceuticals offer significant profit margins and have been proven to be effective in treating a myriad of diseases, they are generally associated with high costs of development and complex manufacturing protocols; this is true for antibody-based products as well. Presently, there are a number of companies that claim to offer end-to-end solutions, ranging from antibody development to commercial production. Further, prevalent trends suggest that sponsor companies are likely to continue relying on contract service providers for various aspects of antibody-based product development and manufacturing.

To order this 285+ page report, which features 100+ figures and 110+ tables, please visit this - https://www.rootsanalysis....

Key Market Insights

Over 100 CMOs presently claim to offer manufacturing services for antibodies
The Antibody Contract manufacturing market is currently dominated by the presence of small and mid-sized companies, which represent 70% of the industry stakeholders. It is also worth highlighting that more than 55% of CMOs claim to have the capabilities to manufacture antibodies across all scales of operation (preclinical, clinical and commercial).

More than 90% service providers are focused on the production of monoclonal antibodies
However, players based in Asia are now increasingly focusing on the development of bispecific antibodies for therapeutic use. It worth highlighting that close to 20% of the CMOs engaged in this domain claim to offer manufacturing services for both bispecific antibodies and antibody fragments.

Europe has emerged as a key manufacturing hub for antibody-based products
More than 120 manufacturing facilities have been established by various players, worldwide; of these, 40% are in Europe. Additionally, 40% of the total installed capacity is in Europe, followed by Asia. Some of the prominent regions in Asia include (in decreasing order of number of manufacturing facilities) China, South Korea, India, Japan and Taiwan.

More than 90 partnership agreements have been inked between 2013 and 2019
Majority of these agreements were focused on manufacturing of various types of antibodies. Other popular types of collaboration models include process development and manufacturing agreements (22%), product development and manufacturing agreements (10%) and licensing agreements (7%).

Multiple expansion initiatives were undertaken by CMOs between 2017 and 2019
More than 50% of such initiatives were reported to be focused on the expansion of manufacturing facilities, followed by building new facilities (38%). It is worth noting that close to 50% of the total number of expansion initiatives were undertaken in Europe, of which, 25% were in the UK.

Demand for therapeutic antibodies is anticipated to grow at a CAGR of 10%, during 2020-2025
Given the fact that there are a number of antibody-based products in the market, the commercial demand for antibodies is significantly higher than the clinical demand. Across the three major global regions, North America represent over half of the overall global manufacturing demand for antibodies.

North America and Europe are anticipated to capture over 70% of the market share by 2030
However, the market in the Asia is anticipated to grow at a relatively faster rate. Further, presently, more than 90% of the antibodies are being developed using mammalian expression systems, and this trend is unlikely to change significantly in short to mid-term.

To request a sample copy / brochure of this report, please visit this- https://www.rootsanalysis....

Key Questions Answered
 Who are the leading CMOs engaged in the production of antibody-based therapeutics?
 What kind of partnership models are commonly adopted by stakeholders in this industry?
 What is the annual clinical and commercial demand for antibody-based products?
 What is the current installed capacity for manufacturing of antibodies?
 What are the various expansion initiatives undertaken by antibody CMOs?
 How is the current and future market opportunity likely to be distributed across key market segments?

The USD 17 billion (by 2030) financial opportunity within the antibody contract manufacturing market has been analyzed across the following segments:
 Type of Antibodies
 Monoclonal Antibodies
 Bispecific Antibodies
 ADCs
 Others

 Company Size
 Small
 Mid-sized
 Large / Very Large

 Scale of Operation
 Preclinical / Clinical
 Commercial

 Type of expression system used
 Mammalian
 Microbial

 Key geographical regions
 North America
 Europe
 Asia and RoW

The report features inputs from eminent industry stakeholders, according to whom antibody therapeutics developers are increasingly outsourcing their manufacturing operations owing to complex nature of the overall process, as well as the high investments associated with setting-up in-house expertise. The report includes detailed transcripts of discussions held with the following experts:
 Dietmar Katinger (Chief Executive Officer, Polymun Scientific)
 David C Cunningham (Director, Corporate Development, Goodwin Biotechnology)
 Claire Otjes (Marketing Manager, Batavia Biosciences)

The research covers profiles of key players that offer manufacturing services for antibodies, featuring a company overview, information on their respective service portfolios, manufacturing facilities and capa

The progressive supranuclear palsy (PSP) therapies market, is anticipated to grow at an annualized rate of over 35% till 2030, predicts Roots Analysis

The exact cause of this rare disorder, which affects 5-17 in 100,000 people, is unknown; however, a complex interplay between different risk factors, including age, genetics and environment, is likely to contribute to the onset of this rare tauopathy

London

Roots Analysis has announced the addition of “Progressive Supranuclear Palsy Therapies Market, 2021-2030” report to its list of offerings.

Presently, there is no cure for PSP and the effectiveness of prescribed generic medications and non-drug therapies to improve the quality of life in patients, is limited. The high unmet patient need and rising caregiver burden has inspired several players to focus their efforts on the development of therapies to control the progression of PSP or manage its symptoms. Consequently, multiple orphan designated drugs, currently in phase II of development, are anticipated to enter the market in the next 3-6 years.

To order this 100+ page report, which features 70+ figures, please visit https://www.rootsanalysis....

Key Market Insights

Currently, over 20 drugs are being developed across preclinical and clinical stages
Majority (50%) of the drug candidates are being evaluated in phase I clinical studies to ease the complexities associated with PSP. Further, owing to their ability to cross the blood-brain barrier, small molecule drugs represent ~70% of the PSP pipeline; this is followed by anti-tau antibodies and antisense oligonucleotides. Since majority of the drugs are small molecules, oral route is the most preferred route.

Close to 20 industry and non-industry players are engaged in the development of drugs for PSP
Majority of the industry players (59%) are small firms / start-ups (with less than 50 employees). North America is the current hub, where close to 60% players are based. Further, a few non-industry players, including Washington University and Scripps Research, are leading the development of several early- stage PSP programs.

More than 100 trials, related to PSP, were registered in the last two decades
It is worth mentioning that around 52% of the trials were / are being conducted in Europe and Asia-Pacific region, however, more than 60% of the patients are enrolled in clinical trials conducted in North America. Further, most of the studies are focused on investigating tau targeted radiopharmaceuticals for PSP.

Around 80 eminent scientists, clinicians and industry veterans, with specialization in neurobiology, emerged as key opinion leaders (KOLs), in this domain
Nearly 50% of these KOLs are associated with organizations based in Europe, followed by North America. Multiple individuals from University of California, San Francisco and Toulouse Hospital and University Center are involved in clinical studies for PSP drugs. Further, 76% of these KOLs have doctoral degrees, namely MD and PhD.

Grants worth over USD 300 million have been awarded to support PSP research, since 2010
Till July 2021, over 700 grants have been disbursed to various companies / organizations working in this domain. National Institute on Ageing and National Institute of Neurological Disorders and Stroke emerged as the most active funding institutes, contributing to over 90% of the total grant amount.

In the last two decades, ~2400 articles on PSP, have been published in neuroscience journals
Over the years, there has been a gradual rise in the number of publications related to PSP; nearly 50% of the articles have been published since 2017. With over 150 articles, Parkinsonism & Related Disorders and Journal of Movement Disorders emerged as the key journals.

Several partnerships were established by stakeholders in this domain, since 2015
More than 75% of the reported deals were established since 2018, with the maximum activity being reported in 2019. Majority of the instances captured in the report were research and development agreements (33%), followed by licensing agreements (25%).

By 2030, curative therapies, targeting molecular mechanism underlying PSP, are likely to represent over 90% of the market share (in terms of sales revenue)
Growth in this domain is anticipated to be driven by the lack of competition from generics and consequently steering adoption of high-priced curative treatments. It is worth noting that US is likely to capture the highest market share (over 65%). Further, the market in Europe is anticipated to grow at a CAGR of ~25%, in the period 2024-2030.

To request a sample copy / brochure of this report, please visit https://www.rootsanalysis....

Key Questions Answered
 What are the prevalent R&D trends related to PSP?
 What are the key challenges faced by stakeholders developing PSP therapies?
 Which are the principal therapies being developed for PSP?
 Who are the leading industry and non-industry players in the PSP therapies market?
 Which are the key geographies where research on PSP is being conducted?
 Which are the leading administering institute centers supporting the research related to PSP therapies?
 Who are the key opinion leaders / experts that have contributed to the domain of PSP therapies?
 What kind of partnership models are commonly adopted by stakeholders engaged in this industry?
 What are the factors that are likely to influence the evolution of PSP therapies market?
 How is the current and future market opportunity likely to be distributed across key market segments?

The USD 492 million (by 2030) financial opportunity within the PSP market has been analyzed across the following segments:
 Phase II Drugs
 AZP2006
 RT001
 BRAVYL
 Emeramide
 NORTHERA

 Type of Treatment
 Curative
 Symptomatic / Palliative

 Key Geographical Reg

The light activated therapies market is anticipated to grow at an annualized rate of 27.7% till 2030, claims Roots Analysis

Light activated therapies are considered to be a transformative approach owing to their capability to eradicate diseased cells from the body with minimal side effects; presenting lucrative opportunities for players engaged in the development of such products

London

Roots Analysis has announced the addition of “Light Activated Therapies Market: Focus on Photodynamic Therapies, Photoimmunotherapies and Photothermal, 2021-2030“ report to its list of offerings.

Rising prevalence of skin disorders is expected to promote the adoption of light activated therapies, making it one of the relatively faster growing segments of this industry. The growing interest of pharmaceutical stakeholders in this field is also reflected from the recent rise in clinical trials registered for such therapy candidates. With multiple therapeutic leads in mid to late development stages (phase II and above), the light activated therapies market is likely to witness significant growth in the foreseen future.

To order this 140+ page report, which features 80+ figures and 120+ tables, please visit https://www.rootsanalysis....

Key Market Insights

More than 125 marketed / under development light activated therapies form the current pipeline
At present, 13% of such therapies are marketed, while majority (82%) of the aforementioned candidates are still being evaluated in clinical phases. Examples of approved therapies include Ameluz®, Foscan®, Hemoporfin®, Metvix®, Photofrin® and Sarotalocan®.

Over 485 clinical trials are currently evaluating light activated therapies, worldwide
It is worth mentioning that most of the trials were / are being conducted in North America (34%). More than 28% patients enrolled in trials conducted in the aforementioned region were recruited across different sites in the United States. Further, 69% of the trials are being sponsored by non-industry players.

Over 635 patents have been filed / granted for light activated therapies, since 2018
Over 35% of these intellectual property documents were filed / granted in the North America, with maximum number of patents being filed in US. This is followed by Europe (33%), Asia Pacific and rest of the world (30%).

By 2030, the opportunity within the light activated therapies market is likely to be dominated by the North America
Growth in this domain is anticipated to be primarily driven by encouraging clinical trial results and likely approval of several advanced stage therapy candidates. Further, Europe and North America (primarily the US) are expected to capture over 80% share of the total market (in terms of sales-based revenues), in 2030.

To request a sample copy / brochure of this report, please visit https://www.rootsanalysis....

Key Questions Answered
 What are the prevalent R&D trends related to light activated therapies?
 What are the key therapeutic areas for which light activated therapies have been / are being developed?
 What are the key challenges faced by stakeholders engaged in the manufacturing of light activated therapies?
 Who are the leading industry and non-industry players engaged in the development of light activated therapies?
 Across which geographies, extensive research related to light activated therapies is being conducted?
 Which factors are likely to influence the evolution of this upcoming market?
 How is the current and future market opportunity likely to be distributed across key market segments?

The financial opportunity within the light activated therapies market has been analyzed across the following segments:

 Target Indication
 Head and Neck Cancer
 Actinic Keratosis
 Macular Degeneration,
 Polypoidal Choroidal Vasculopathy
 Cervical Intraepithelial Neoplasia
 Bladder Cancer
 Barrett’s Esophagus
 Gastric Cancer
 Lung Cancer
 Port-Wine Stain
 Others

 Key Players

 Key Geographical Regions
 North America
 Europe
 Asia Pacific

The research includes detailed profiles of key players (listed below); each profile features an overview of the company, its financial information (if available), details on product portfolio and recent developments, as well as an informed future outlook.
 ADVANZ PHARMA
 Biofrontera
 biolitec Pharma
 Luzitin
 Nanospectra Biosciences
 Photoatomic
 Rakuten Medical
 Steba biotech
 Theralase

For additional details, please visit
https://www.rootsanalysis....

You may also be interested in the following titles:
1. Fc Fusion Therapeutics Market: Industry Trends and Global Forecasts, 2020-2030
2. CRISPR Based Therapeutics Market: Industry Trends and Global Forecasts, 2020-2030
3. Cell and Gene Therapy CROs Market (2nd Edition): Industry Trends and Global Forecasts, 2021-2030
4. TIL-based Therapies Market: Industry Trends and Global Forecasts, 2021-2030
5. TCR-based Therapies Market: Industry Trends and Global Forecasts, 2021-2030
6. CAR-T Cell Therapies Market: Industry Trends and Global Forecasts, 2021-2030

Contact Details
Ben Johnson
+1 (415) 800 3415
ben.johnsonrootsanalysis.com

Roots Analysis
Web: https://www.rootsanalysis....
LinkedIn: https://in.linkedin.com/co...
Twitter: https://twitter.com/RootsA...
Medium: https://medium.com/RootsA...
Pinterest: https://in.pinterest.com/R...
Quora: https://rootsanalysisinsig...

Elon Musk will open his own university.

He tweeted that he plans to open a University of Technology and Science in Texas.

Musk wants to name the university Texas Institute of Technology & Science. The media noted that the acronym would sound like a vulgar name for a woman's breast - TITS). Musk also said that the university will have "epic merch", which will be able to inspire everyone's admiration.

Hola chicos estan invitados a este proyecto nuevo, es bastante nuevo si les gusta algunas cosas relacionada al arte anime, programacion entre otras podremos hacer cosas interesante, bueno si mas dilacion paso a dejar el enlace espero que les guste este nuevo proyecto o remake de proyecto.
#colibrism #test #Nicki #hepinizamk #seekingturkey #kapatilsin #ziyaselcuk #Science #iOS #fotolog

Nothing found!

Sorry, but we could not find anything in our database for your search query {{search_query}}. Please try again by typing other keywords.